Physician profile
Leah I Akinseye
NPI 1952781064
$13,777.79
in general payments reported to CMS, 2019-2025
36 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $447 · 2023: $1,060 · 2024: $1,136 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,149 · Consulting Fee: $3,750 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,315 · Travel and Lodging: $2,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,148.91 |
| Consulting Fee | $3,750.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,315.00 |
| Travel and Lodging | $2,116.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,128.87 | 2022-2025 | |
| Biomarin Pharmaceutical INC. | $4,483.06 | 2023-2025 | Voxzogo 1.2mg |
| Novo Nordisk INC | $654.35 | 2022-2025 | Ozempic, Rybelsus, Norditropin |
| Abbvie INC. | $429.40 | 2022-2025 | Lupron Depot |
| Insulet Corporation | $372.09 | 2023-2025 | Omnipod |
| Sequel Med Tech, LLC | $352.08 | 2024-2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $240.29 | 2022-2025 | Skytrofa |
| Xeris Pharmaceuticals, INC. | $226.99 | 2022-2024 | Gvoke Hypopen, Recorlev |
| Alexion Pharmaceuticals, INC. | $205.39 | 2022-2025 | Strensiq |
| Lilly USA, LLC | $182.01 | 2022-2024 | Zepbound, Jardiance |
| Beta Bionics, INC. | $147.83 | 2024 | Ilet Bionic Pancreas |
| Azurity Pharmaceuticals, INC. | $146.09 | 2022-2025 | Triptodur |
| Corcept Therapeutics | $145.88 | 2024-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $137.16 | 2023-2025 | |
| Pfizer INC. | $129.01 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $128.11 | 2025 | |
| Abbott Laboratories | $115.56 | 2024-2025 | Freestyle Libre, Eterna |
| Recordati_rare_diseases_inc. | $61.41 | 2023-2025 | Isturisa, Signifor Lar |
| Chiesi USA, INC. | $55.76 | 2024-2025 | Mycapssa, Myalept |
| Hologic Sales and Service, LLC | $51.26 | 2023-2024 | Coolseal Generator |
| Radius Health, INC. | $45.14 | 2023 | Tymlos |
| Endo Pharmaceuticals INC. | $38.26 | 2023-2024 | Supprelin |
| Cequr Corporation | $37.72 | 2024-2025 | Cequr Simplicity |
| Madrigal Pharmaceuticals | $29.94 | 2025 | Rezdiffra |
| Rhythm Pharmaceuticals, INC. | $24.68 | 2024 | Imcivree |
| Neurocrine Biosciences, INC. | $23.98 | 2025 | |
| Amryt Pharma Holdings Ltd | $23.34 | 2023 | Mycapssa |
| Antares Pharma, INC. | $20.94 | 2024 | Xyosted |
| Eton Pharmaceuticals, INC. | $19.90 | 2023 | Alkindi |
| Regeneron Healthcare Solutions, INC. | $19.85 | 2022 | |
| Tandem Diabetes Care, INC. | $19.09 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Endo USA, INC. | $18.35 | 2025 | Supprelin |
| Grt US Holding, INC. | $17.27 | 2022 | |
| Soleno Therapeutics, INC. | $17.25 | 2025 | Vykat Xr |
| Arbor Pharmaceuticals, INC. | $16.04 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.44 | 2024 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Akinseye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.